Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The FEBS Journal

• Publication date

  2006-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1742-4658.2006.05410.xPMID 16934036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.

  2005cited by this paper
• Rational Design and Synthesis of Highly Potent -Glucocerebrosidase Inhibitors

  2005cited by this paper
• Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.

  2005cited by this paper
• Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors.

  2005cited by this paper
• ERAD: the long road to destruction

  2005cited by this paper
• Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.

  2005cited by this paper
• Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease

  2004cited by this paper
• N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.

  2004influential reference
• Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff Patients*

  2004cited by this paper
• Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17.

  2004cited by this paper
• N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease

  2004influential reference
• Pharmacological chaperones: potential treatment for conformational diseases.

  2004cited by this paper
• Therapeutic approaches to protein-misfolding diseases

  2003cited by this paper
• The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement

  2003cited by this paper
• A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.

  2003cited by this paper
• X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease

  2003influential reference
• Chemical chaperone therapy for brain pathology in GM1-gangliosidosis

  2003cited by this paper
• Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.

  2003cited by this paper
• Australine and related alkaloids: easy structural confirmation by 13C NMR spectral data and biological activities

  2003cited by this paper
• Gaucher Disease

  2002cited by this paper
• Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease

  2002influential reference
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.).

  2001cited by this paper
• In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.

  2000cited by this paper
• Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.

  2000cited by this paper
• Polyhydroxylated pyrrolidine and piperidine alkaloids from Adenophora triphylla var. japonica (Campanulaceae).

  2000cited by this paper
• Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

  2000cited by this paper
• Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells.

  2000cited by this paper
• Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

  1999cited by this paper
• 1-N-Iminosugars: Potent and Selective Inhibitors of β-Glycosidases

  1998cited by this paper
• New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.

  1998cited by this paper
• Folding of secretory and membrane proteins.

  1998cited by this paper
• Specific alpha-galactosidase inhibitors, N-methylcalystegines--structure/activity relationships of calystegines from Lycium chinense.

  1997cited by this paper
• N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.

  1995cited by this paper
• Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.

  1994cited by this paper
• Gaucher disease. Enzymology, genetics, and treatment.

  1993cited by this paper
• Enzyme replacement therapy in type I Gaucher disease.

  1991cited by this paper
• METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

  1965cited by this paper

• C-2 fluorinated castanospermines as potent and specific α-glucosidase inhibitors: synthesis and structure-activity relationship study.

  2025cites this paper
• In vitro comparison of the glycosidase inhibitory profile of isoiminosugars with their 1- and 5a-modified derivatives.

  2025cites this paper
• Stereodivergent synthesis and antiproliferative profile of C-tridecyl piperidine-3,4,5-triols

  2025cites this paper
• Acetal functionalized iminosugars for targeting β-glucocerebrosidase modulation.

  2025cites this paper
• Iminosugar‐Dihydroazulenes as Mutant L444P Glucocerebrosidase Enhancers

  2024cites this paper
• Design and synthesis of iso-allo-DNJ and L-isoDALDP derivatives: pursuit of potent and selective inhibitors of α-glucosidase.

  2023cites this paper
• Animal Models for the Study of Gaucher Disease

  2023cites this paper
• GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders

  2022cites this paper
• Update of treatment for Gaucher disease.

  2022cites this paper
• Nanomolar β-glucosidase and β-galactosidase inhibition by enantiomeric α-1-C-alkyl-1,4-dideoxy-1,4-imino-arabinitol derivatives.

  2022cites this paper
• trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.

  2022cites this paper
• Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach.

  2021cites this paper
• Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses

  2021cites this paper
• Glycosylation in health and disease

  2019cites this paper
• Biological activities of 3,4,5‐trihydroxypiperidines and their N‐ and O‐derivatives

  2018cites this paper
• Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

  2018cites this paper
• Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation

  2018cites this paper
• OVERVIEW OF GAUCHER DISEASE AND ITS MANAGEMENT

  2017cites this paper
• Fluorinated Chaperone-β-Cyclodextrin Formulations for β-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease.

  2017cites this paper
• Glucosylceramide metabolism: from 3D structure to the development of selective chemical probes

  2017cites this paper
• New Directions in Gaucher Disease

  2016cites this paper
• Ketenimine mediated synthesis of lactam iminosugars: development of one-pot process via tandem hydrative amidation of amino-alkynes and intramolecular transamidation

  2016cites this paper
• Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases.

  2016cites this paper
• Treatment options for patients with Gaucher disease

  2016cites this paper
• Chaperones as potential therapeutics for Krabbe disease

  2016cites this paper
• Small Molecules Substrate Inhibitors, Chaperones, Stop-Codon Read Through, and Beyond

  2016cites this paper
• Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease.

  2016cites this paper
• Concise synthesis of calystegines B2 and B3via intramolecular Nozaki-Hiyama-Kishi reaction.

  2016cites this paper
• Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.

  2016cites this paper
• Combined Therapies for Lysosomal Storage Diseases.

  2015cites this paper
• Design and Synthesis of Labystegines, Hybrid Iminosugars from LAB and Calystegine, as Inhibitors of Intestinal α-Glucosidases: Binding Conformation and Interaction for ntSI.

  2015cites this paper
• Human Acid β‐Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease

  2015cites this paper
• Prenatal Diagnosis of Disorders of Lipid Metabolism

  2015cites this paper
• Expression and Purification of Human Lysosomal β-galactosidase from Pichia Pastoris

  2014cites this paper
• Iminosugars: Therapeutic Applications and Synthetic Considerations

  2014cites this paper
• Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators

  2014cites this paper
• Activity-based probes for retaining β-glucosidases: Novel tools for research and diagnostics

  2014cites this paper
• Treatment of lysosomal storage disorders: successes and challenges

  2014cites this paper
• Treatment of lysosomal storage diseases: recent patents and future strategies.

  2014cites this paper
• Synthesis of isofagomine-pyrrolidine hybrid sugars and analogues of (-)-steviamine and (+)-hyacinthacine C5 using 1,3-dipolar cycloaddition reactions.

  2014cites this paper
• Glucocerebrosidase Enhancers for Selected Gaucher Disease Genotypes by Modification of α‐1‐C‐Substituted Imino‐D‐xylitols (DIXs) by Click Chemistry

  2014cites this paper
• The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases

  2014cites this paper
• Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.

  2014cites this paper
• BETA-GLUCOSIDASE 2 ( GBA 2 ) ACTIVITY AND IMINO SUGAR PHARMACOLOGY

  2013cites this paper
• An improved methodology for the synthesis of 1-C-allyl imino-d-xylitol and -l-arabinitol and their rapid functionalization

  2013cites this paper
• Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase

  2013cites this paper
• Pharmacological chaperones as therapeutics for lysosomal storage diseases.

  2013cites this paper
• Glucocerebrosidase inhibitors for the treatment of Gaucher disease.

  2013cites this paper
• Commentary on "Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease" by Zimran et al.

  2013cites this paper
• β-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology*

  2013cites this paper
• Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.

  2013cites this paper
• Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.

  2013cites this paper
• Isolation and Identification of Myo-Inositol Crystals from Dragon Fruit (Hylocereus polyrhizus)

  2012cites this paper
• Gaucher disease paradigm: From ERAD to comorbidity

  2012cites this paper
• Pharmacological chaperone therapy for Fabry disease

  2012cites this paper
• Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.

  2012cites this paper
• Non-iminosugar glucocerebrosidase small molecule chaperones.

  2012cites this paper
• Review Pharmacological chaperone therapy for Fabry disease

  2012cites this paper
• Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.

  2012cites this paper
• The role of saposin C in Gaucher disease.

  2012cites this paper
• Protein Trafficking Diseases

  2012cites this paper
• Asymmetric synthesis of polyhydroxylated N-alkoxypiperidines by ring-closing double reductive amination: facile preparation of isofagomine and analogues.

  2012cites this paper
• Towards a stable noeuromycin analog with a D-manno configuration: synthesis and glycosidase inhibition of D-manno-like tri- and tetrahydroxylated azepanes.

  2012cites this paper
• Advances in the synthesis of calystegines and related products and their biochemical properties.

  2012cites this paper
• Recent advances in treatment approaches to Gaucher disease.

  2011cites this paper
• Aproximació terapèutica per a la malaltia de Gaucher basada en xaperones

  2011cites this paper
• Nous ciclitols com a inhibidors de la glucocerebrosidasa. Aplicació al disseny de xaperones farmacològiques per al tractament de la malaltia de Gaucher

  2011cites this paper
• Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues.

  2011cites this paper
• Second‐Generation Iminoxylitol‐Based Pharmacological Chaperones for the Treatment of Gaucher Disease

  2011cites this paper
• Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

  2011cites this paper
• Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.

  2011cites this paper
• Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.

  2011cites this paper
• Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

  2011cites this paper
• Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.

  2011cites this paper
• Pharmacological chaperone therapy for Gaucher disease: a patent review

  2011cites this paper
• Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.

  2011cites this paper
• Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease*

  2011cites this paper
• Tailoring the specificity and reactivity of a mechanism-based inactivator of glucocerebrosidase for potential therapeutic applications.

  2011cites this paper
• An approach toward homocalystegines and silyl-homocalystegines. acid-mediated migrations of acetates in seven-membered ring systems.

  2011cites this paper
• Hypersensitive response to over-reactive cysteines.

  2011cites this paper
• Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis

  2011cites this paper
• and Prognosis Progress − Ameliorate Protein Misfolding and Aggregation Diseases Chemical and Biological Approaches for Adapting Proteostasis to service

  2011cites this paper
• Chiral pool synthesis of calystegine A3 from 2-deoxyglucose via a Brown allylation.

  2011cites this paper
• Biophysical and structural characterization of proteins implicated in glaucoma and Gaucher disease

  2011cites this paper
• Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.

  2011cites this paper
• Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

  2011cites this paper
• A Fluorescent sp2‐Iminosugar With Pharmacological Chaperone Activity for Gaucher Disease: Synthesis and Intracellular Distribution Studies

  2010cites this paper
• Molecular probes: Getting lucky in the lysosome.

  2010cites this paper
• Optimal therapy in Gaucher disease

  2010cites this paper
• Carbohydrate mimetics and scaffolds: sweet spots in medicinal chemistry.

  2010cites this paper
• Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S

  2010cites this paper
• The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase

  2010cites this paper
• Ultrasensitive in situ visualization of active glucocerebrosidase molecules.

  2010cites this paper
• Discovery and design of carbohydrate-based therapeutics

  2010cites this paper
• The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases.

  2010cites this paper
• Glycosphingolipide – Natur, Funktion und pharmakologische Modulierung

  2009cites this paper
• Sugar-mimicking glycosidase inhibitors: bioactivity and application

  2009cites this paper
• Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N‐(n‐nonyl)Deoxynojirimycin

  2009cites this paper
• Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.

  2009cites this paper
• Glycomimetics at the mirror: medicinal chemistry of L-iminosugars.

  2009cites this paper